Biofrontera EBITDA per osake

Mitä Biofrontera tekee? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera on yksi Eurpooliin suosituimmista yhtiöistä.